Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 2.02 EUR 5.65% Market Closed
Updated: May 31, 2024

Profitability Summary

Oryzon Genomics SA's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Oryzon Genomics SA

Revenue
0 EUR
Cost of Revenue
-805.7k EUR
Gross Profit
-805.7k EUR
Operating Expenses
-3.5m EUR
Operating Income
-4.3m EUR
Other Expenses
1.4m EUR
Net Income
-2.9m EUR

Margins Comparison
Oryzon Genomics SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
ES
Oryzon Genomics SA
MAD:ORY
124.8m EUR N/A N/A N/A
US
Abbvie Inc
NYSE:ABBV
276B USD
66%
29%
11%
US
Amgen Inc
NASDAQ:AMGN
161.5B USD
66%
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.4B USD
87%
41%
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
106.9B USD
86%
30%
29%
AU
CSL Ltd
ASX:CSL
134.5B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
79.8B USD
76%
32%
2%
US
Moderna Inc
NASDAQ:MRNA
58B USD
22%
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
32B USD
75%
22%
12%
KR
Celltrion Inc
KRX:068270
36.7T KRW
47%
21%
17%
Country ES
Market Cap 124.8m EUR
Gross Margin N/A
Operating Margin N/A
Net Margin N/A
Country US
Market Cap 276B USD
Gross Margin
66%
Operating Margin
29%
Net Margin
11%
Country US
Market Cap 161.5B USD
Gross Margin
66%
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 114.4B USD
Gross Margin
87%
Operating Margin
41%
Net Margin
39%
Country US
Market Cap 106.9B USD
Gross Margin
86%
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 134.5B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 79.8B USD
Gross Margin
76%
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 58B USD
Gross Margin
22%
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 32B USD
Gross Margin
75%
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 36.7T KRW
Gross Margin
47%
Operating Margin
21%
Net Margin
17%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Oryzon Genomics SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
ES
Oryzon Genomics SA
MAD:ORY
124.8m EUR
-4%
-3%
-5%
-2%
US
Abbvie Inc
NYSE:ABBV
276B USD
56%
4%
15%
13%
US
Amgen Inc
NASDAQ:AMGN
161.5B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.4B USD
24%
19%
23%
33%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
106.9B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
134.5B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
79.8B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
58B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
32B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
36.7T KRW
4%
3%
4%
3%
Country ES
Market Cap 124.8m EUR
ROE
-4%
ROA
-3%
ROCE
-5%
ROIC
-2%
Country US
Market Cap 276B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
13%
Country US
Market Cap 161.5B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 114.4B USD
ROE
24%
ROA
19%
ROCE
23%
ROIC
33%
Country US
Market Cap 106.9B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 134.5B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 79.8B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 58B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 32B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 36.7T KRW
ROE
4%
ROA
3%
ROCE
4%
ROIC
3%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More